BioNTech SE (NASDAQ:BNTX, ", BioNTech", )))) and Duality Biologics (Suzhou) Co. Ltd. ("DualityBio") today announced that the U.S. Food and Drug Administration ("FDA") granted
Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces receipt of
Samsung Electronics Co (OTC: SSNLF), a leading South Korean tech company, plans to invest approximately 40 billion yen ($280 million) over five years in a new
Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for